Plain Language Summary Publication: Low-dose psilocybin in short-lasting unilateral neuralgiform headache attacks: Results from an open-label phase Ib ascending dose study

Matt Butler has nothing to declare. Sanjay Cheema: Received a research fellowship sponsored by Abbott. Giorgio Lambru: Co-chair of the Medical Advisory Board of the Trigeminal neuralgia Association (TNA) UK; received personal fees from Abbvie, Teva, Novartis, Eli Lilly, Lundbeck; participated in clinical trials as principal investigator for Novartis, Eli Lilly, Teva, Nevro. Manjit Matharu: Chair of the Medical Advisory Board of the CSF Leak Association, serves on the advisory board for AbbVie, Abbott, Eli Lilly, Kriya, Lundbeck, Pfizer, Salvia and TEVA and has received payment for the development of educational presentations from AbbVie, Eli Lilly, Lunbeck and TEVA. James Rucker: Paid advisory boards for Clerkenwell Health and Delica Therapeutics, paid articles for Janssen, assistance for attendance at conferences from Compass Pathways and Janssen, grant funding from Compass Pathfinder, Beckley PsyTech, Multidisciplinary Association for Psychedelic Studies, National Institute for Health Research, Wellcome Trust, Biomedical Research Centre at the South London and Maudsley NHS Foundation Trust. No shareholdings in pharmaceutical companies. No shareholdings in companies developing psychedelics. Mathieu Seynaeve and Fiona Dunbar are employed by Beckley PsyTech. Catherine Bird, Sadie Hambleton, Kete Campbell-Coker, and Carolina Maggio have no conflicts to disclose.